Gland Pharma Ltd

GLAND PHARMA LIMITED

Gland Pharma Limited has informed the BSE about the cessation of a Non-Executive Non-Independent Director.

GLAND PHARMA LIMITED

Gland Pharma Limited has informed BSE about the appointment of a Non-Executive Non-Independent Director.

GLAND PHARMA LIMITED

Gland Pharma Limited has informed the BSE about the cessation of a non-executive non-independent director.

GLAND PHARMA LIMITED

Gland Pharma Limited has informed the BSE about the cessation of a non-executive non-independent director.

GLAND PHARMA LIMITED

Gland Pharma Limited has informed BSE about the appointment of a Non-Executive Non-Independent Director.

GLAND PHARMA LIMITED

Gland Pharma Limited has informed the BSE about the cessation of a non-executive non-independent director.

GLAND PHARMA LIMITED

Gland Pharma Limited has informed the BSE about the appointment of a Non-Executive Non-Independent Director.

Gland Pharma Ltd

Gland Pharma Ltd has announced the resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent Director and the appointment of Mr. Xingli Wang as an Additional Director. The company has also announced an investment of USD 21 million in Gland Pharma USA Inc. to facilitate expansion of its business in the United States.

Gland Pharma Ltd

Gland Pharma Ltd has announced an investment of USD 21 million in Gland Pharma USA Inc. to subscribe to 60% of the equity share capital of Novelstar Pharma Inc. The company also announced the resignation of a director and the appointment of a new director.

Gland Pharma Ltd

Gland Pharma Ltd has announced the outcome of its board meeting held on October 01, 2026. The board has approved an investment of USD 21 million in Gland Pharma USA Inc., a wholly-owned subsidiary, to subscribe to 60% of the equity share capital of Novelstar Pharma Inc. Additionally, Mr. Wenjie Zhang has resigned as a Non-Executive & Non-Independent Director, and Mr. Xingli Wang has been appointed as an Additional Director. The committees of the board have been realigned in compliance with the Listing Regulations.

Gland Pharma Ltd

Fosun Pharma Industrial Pte Ltd has made a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or significant stake acquisition in Gland Pharma Ltd.

Gland Pharma Ltd

Gland Pharma Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026.

Gland Pharma Ltd

Gland Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Mirae Asset Mutual Fund, indicating a potential change in shareholding.

Gland Pharma Ltd

Gland Pharma Ltd has published a notice in newspapers to inform shareholders to register or update their email addresses for receiving statutory communications in electronic form.

Gland Pharma Ltd

Gland Pharma Ltd has announced the acquisition of 100% equity share capital of Gland Pharma USA Inc., a wholly-owned step-down subsidiary, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company. The acquisition is expected to be completed by October 31, 2026.

Gland Pharma Ltd

Gland Pharma Ltd has informed that its Board of Directors has approved the acquisition of 100% equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company. The acquisition is expected to be completed by October 31, 2026.

Gland Pharma Ltd

Gland Pharma Ltd has allotted 44,193 equity shares on exercise of ESOPs, increasing its issued, subscribed and paid-up share capital to Rs. 165,010,854.

Gland Pharma Ltd

Gland Pharma Ltd has granted 5,90,249 employee stock options to 124 employees under the Gland Pharma Employee Stock Option Scheme, 2025, at an exercise price of INR 1,461.15 and INR 1 per share.

Gland Pharma Ltd

Gland Pharma Ltd has been fined ₹70,000 each by BSE and NSE for a technical breach of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has paid the fines and taken steps to ensure compliance with the applicable provisions of the Listing Regulations.

Gland Pharma Ltd

Gland Pharma Ltd has announced a schedule of Analyst/Institutional Investor Meetings on September 11, 2026, with DSP Mutual Fund for a one-on-one meeting.